

Human CellExp™ Recombinant EBOV Envelope Glycoprotein 1

GP1, GP, Envelope glycoprotein, GP2 Catalog # PBV11540r

Specification

Human CellExp™ Recombinant EBOV Envelope Glycoprotein 1 - Product info

Primary Accession P87666

Calculated MW 51.6 kDa KDa

Human CellExp™ Recombinant EBOV Envelope Glycoprotein 1 - Additional Info

Other Names

GP1, GP, Envelope glycoprotein, GP2

Gene Source Source Assay&Purity Recombinant **Target/Specificity** Zaire ebolavirus HEK 293 cells SDS-PAGE;> 95%

GP

Application Notes

Reconstitute in 1X PBS to the desired protein concentration.

Format

Lyophilized

Storage

-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

Human CellExp™ Recombinant EBOV Envelope Glycoprotein 1 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Human CellExp™ Recombinant EBOV Envelope Glycoprotein 1 - Images

Human CellExp™ Recombinant EBOV Envelope Glycoprotein 1 - Background

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40),





Tel: 858.875.1900 Fax: 858.875.1999

GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly. GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.